THE USE OF MULTI-CRITERIAL DECISION ANALYSIS (MCDA) FOR ESTIMATING THE THERAPEUTIC VALUE OF INNOVATIVE DRUGS

Фармакоэкономика

V. V. Omelyanovskiy¹  G. R. Khachatryan²  N. Z. Musina³  V. K. Fedyaeva⁴  O. I. Ivakhnenko⁴ 

[1] Research Financial Institute of the Ministry of Finance of the Russian Federation;I.M. Sechenov First Moscow State Medical University;Institute of Applied Economic Research of RANEPA, Research Financial Institute of the Ministry of Finance of the Russian Federation;Institute of Applied Economic Research of the Russian Presidential Academy of National Economy and Public Administration;

关键词: value-based pricing;    innovative medicines;    innovations;    multi-criteria decision analysis;    mcda;   

DOI  :  10.17749/2070-4909.2017.10.2.069-074

来源: DOAJ

【 摘 要 】

Among the most important aspects of the health policy are the methods for pricing of medicines, especially of innovative medicines. In many countries, the “therapeutic value” of a medicine is commonly used as a major criterion in negotiations on medicine prices. The existing tools for assessing the therapeutic value of medicines are not used in the Russian Federation. Here we propose a method for estimating the therapeutic value of innovative medicines based on the multi-criterial analysis.

【 授权许可】

Unknown